Arca Biopharma (ABIO) Upgraded to “Sell” by ValuEngine
Arca Biopharma (NASDAQ:ABIO) was upgraded by analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a report issued on Friday.
Shares of Arca Biopharma (NASDAQ ABIO) opened at $1.75 on Friday. Arca Biopharma has a 52 week low of $1.05 and a 52 week high of $2.80. The company has a market capitalization of $20.93, a price-to-earnings ratio of -0.91 and a beta of 1.90.
Arca Biopharma (NASDAQ:ABIO) last announced its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.39) EPS for the quarter.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/02/01/arca-biopharma-abio-upgraded-to-sell-by-valuengine.html.
Arca Biopharma Company Profile
ARCA biopharma, Inc (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF).
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Arca Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arca Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.